) The high cure rate of germ cell tumors (GCTs) challenges us to identify patients destined to fail standard therapies. We hypothesize that PCR for beta-HCG and AFP RNA can detect circulating GCT cells and provide prognostic information based on the metastatic potential of GCTs.
The specific aims of this proposal are:
Specific Aim 1 : Evaluate PCR for beta-HCG as a diagnostic tool in predicting disease relapse after autologous marrow and stem cell transplantation (AuBMT) for GCTs. In a pilot study, beta-HCG PCR detected circulating tumor cells in the apheresis products of approximately one-third of GCT patients undergoing AuBMT. We hypothesize that detection of circulating tumor cells will predict relapse after AuBMT.
We aim to test this hypothesis and also determine if beta-HCG PCR can be utilized to monitor tumor cell depletion methods, specifically CD34 selection.
Specific Aim 2 : Evaluate PCR for beta-HCG as a prognostic tool in patients undergoing initial chemotherapy and those treated with surgery alone. Our preliminary evidence indicates that mRNA for beta-HCG can be detected in the blood of certain GCT patients at diagnosis. We hypothesize that beta- HCG PCR at diagnosis can be used to predict relapse after standard GCT therapies. We proposed to study the same patients undergoing initial chemotherapy treatment being evaluated in Projects 1-3 and analyzed in the prognostic models being tested in Core B.
Specific Aim 3 : Define beta-HCG gene expression within the beta-HCG locus in GCTs and develop alternate diagnostic tools in detecting circulating GCT cells in tumors that do not express beta-HCG. The beta-HCG gene locus contains six gene copies. We propose to evaluate GCT samples for the expression of beta-HCG genes within the beta-HCG gene locus and determine whether detected difference can be exploited for diagnostic and predictive testing. Also, approximately one-third of GCT in advanced GCT patients do not express beta-HCG but may express other molecules. We will evaluate expression of alpha fetoprotein (AFP) as an alternative molecular marker in patients whose tumors do not express beta-HCG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA074295-03
Application #
6493052
Study Section
Project Start
2001-08-22
Project End
2003-07-31
Budget Start
Budget End
Support Year
3
Fiscal Year
2001
Total Cost
$254,104
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Juric, Dejan; Sale, Sanja; Hromas, Robert A et al. (2005) Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. Proc Natl Acad Sci U S A 102:17763-8
George, David W; Foster, Richard S; Hromas, Robert A et al. (2003) Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 21:113-22
Madani, A; Kemmer, K; Sweeney, C et al. (2003) Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol 14:873-80
Guo, Ying; Costa, Robert; Ramsey, Heather et al. (2002) The embryonic stem cell transcription factors Oct-4 and FoxD3 interact to regulate endodermal-specific promoter expression. Proc Natl Acad Sci U S A 99:3663-7
Soule, S; Baldridge, L; Kirkpatrick, K et al. (2002) HER-2/neu expression in germ cell tumours. J Clin Pathol 55:656-8
Richkind, K; Hromas, R; Lytle, C et al. (2000) Identification of two new translocations that disrupt the AML1 gene. Cancer Genet Cytogenet 122:141-3
Hromas, R; Shopnick, R; Jumean, H G et al. (2000) A novel syndrome of radiation-associated acute myeloid leukemia involving AML1 gene translocations. Blood 95:4011-3